Skip to content
You are now leaving to visit

Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA

CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA) an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today announced that they received a Complete Response Letter (CRL) from the Division of